Antipsychotic Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

The market is segmented by Application (Schizophrenia, Bipolar disorder, Unipolar depression, Dementia, Others), Drug Classification, and Geography

Market Snapshot

Antipsychotic Drugs-1
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

3.5%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The rise in the prevalence of mental health disorders, such as schizophrenia and bipolar disorder amongst the population is a major growth driver for the market. According to the Anxiety and Depression Association of America, around 16.1 million adults aged 18 years or older were suffering from depression in the United States during the year 2015-2016.

World Health Organization (WHO) have recommended mental health action plan to promote mental health and preventing mental disorders in the member states. In addition, according to the key facts published by WHO, an estimated 300 million people are affected by depression and 60 million people are affected by bipolar disorder, worldwide. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience the ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable.

Therefore, it is indicated that the market will majorly be driven by the rising prevalence of mental disorders.

Scope of the Report

Antipsychotic drugs are the medications used in the treatment of psychosis including schizophrenia, and bipolar disorder.

By Application
Schizophrenia
Bipolar Disorder
Unipolar Disorder
Dementia
Others
By Drug Classification
First Generation
Second Generation
Third Generation
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Schizophrenia is Expected to Register a Highest CAGR Over the Forecast Period

Schizophrenia is a serious mental disorder and is affecting the large number of people across the globe. The disease is mainly characterized by the distortions in thinking, emotions, and sense of self and behavior. World Health Organization has stated that around 23 million people across the globe are affected by this disorder among which 12 million are male and 9 million are females. National Institute of Mental Health has stated that the prevalence of Schizophrenia and related symptoms is around 0.25% and 0.64% and this is increasing rapidly. This rise in the prevalence of the disease is contributing to the market growth.

As the disease is serious and it increases the chances of early death if not treated properly, there is a growing focus of companies to come up with the novel drugs for the treatment of this disease. Currently, there are several drugs available in the market and are approved by the US FDA. For instance, Chlorpromazine, Aripiprazole, Olanzapine, etc.

Antipsychotic Drugs-2

To understand key trends, Download Sample Report

Asia-Pacific to Witness the Fastest Growth Rate Over the Forecast Period

Asia-Pacific is expected to witness the fastest growth rate during the forecast period. The healthy CAGR is expected due to rising social awareness regarding psychotic disorders and other associated disorders, such as mania, anxiety, and depression. The growing access and availability of medications for the treatment of a mental illness are expected to propel the growth of the market. North America is expected to dominate the market share, owing to well-established healthcare infrastructure, better regulatory framework, and government support in the countries of this region.

Antipsychotic Drugs-3

To understand geography trends, Download Sample Report

Competitive Landscape

The market for Antipsychotic Drugs is moderately competitive and consists of the global players as well as the local players. Since most of the drugs for the treatment of the disease are approved bu the FDA, global players are currently holding a major share of the market. Due to the rising focus of the small players for market penetration, it is believed that these players will hold a substantial share of the market in the coming future.

Major Players

  1. AstraZeneca
  2. Eli Lily and Company
  3. Johnson and Johnson
  4. Pfizer Inc.
  5. Allergan

* Complete list of players covered available in the table of contents below

Antipsychotic Drugs-4

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Mental Disorders

      2. 4.2.2 Increasing Focus of Governments and Health Care Organizations on Mental Health

      3. 4.2.3 Constant Investment in Research and Development

    3. 4.3 Market Restraints

      1. 4.3.1 Addiction Caused Due to the Antipsychotic Drugs

      2. 4.3.2 Patent Expiry of Major Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Application

      1. 5.1.1 Schizophrenia

      2. 5.1.2 Bipolar Disorder

      3. 5.1.3 Unipolar Disorder

      4. 5.1.4 Dementia

      5. 5.1.5 Others

    2. 5.2 By Drug Classification

      1. 5.2.1 First Generation

      2. 5.2.2 Second Generation

      3. 5.2.3 Third Generation

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 UK

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Eli Lily and Company

      2. 6.1.2 AstraZeneca

      3. 6.1.3 GlaxoSmithKline

      4. 6.1.4 Johnson & Johnson

      5. 6.1.5 Bristol-Myers Squibb Company

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Allergan

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information